Higher doses lead to more side effects, not necessarily better results
Reproducible Manufacturing: Produced to meet consistent research standards for reliable results
Notably, consumers who may be experiencing digestive issues may be seeking to have more control over their food, and as a result, are eating at home instead of eating out
Orforglipron (Eli Lilly): The Oral Option Eli Lilly is also developing orforglipron, an oral (pill) GLP-1 agonist
Prior authorization requirements are common, requiring documentation of BMI over 30 kg/m or over 27 kg/m with comorbidities, failed attempts at diet and exercise, and sometimes trial of other weight loss medications
Tirzepatide (Personalized Tirzepatide+ / Zepbound / Mounjaro) Tirzepatide is a dual GIP and GLP-1 receptor agonist - meaning it activates two hormone pathways instead of one